ANIX - NASDAQ
Anixa Biosciences, Inc.
$2.61
+3.6%Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
At a Glance
Live Snapshotanix
Total Current Assets
Last Annual Value
15.89M
3-Year CAGR
-19%
5-Year CAGR
11%
10-Year CAGR
9%
Anixa Biosciences, Inc. Competitors Analysis of Total Current Assets
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Anixa Biosciences, Inc. NASDAQ:ANIX | 15.89M | -14.4% | -15.1% | 16.7% | |
 Agenus Inc. NASDAQ:AGEN | 133.44M | 5.9% | -16.7% | 3.9% | |
 VistaGen Therapeutics, Inc. NASDAQ:VTGN | 82.08M | 67.4% | -4.6% | 57.8% | |
 Atossa Therapeutics, Inc. NASDAQ:ATOS | 45.62M | -20.9% | -20.2% | 30.2% | |
 Greenwich LifeSciences, Inc. NASDAQ:GLSI | -6.74M | N/A | N/A | N/A | |
 Tevogen Bio Holdings Inc. NASDAQ:TVGN | 2.36M | 11.1% | -19.9% | N/A | |
 C4 Therapeutics, Inc. NASDAQ:CCCC | 258.11M | -1.6% | -4.5% | N/A | |
 Cardiff Oncology, Inc. NASDAQ:CRDF | 60.13M | -8.1% | -16.3% | 4.4% | |
 Vyome Holdings, Inc. NASDAQ:HIND | 4.59M | -23.6% | -31.3% | -2.2% | |
 Nuvectis Pharma, Inc. NASDAQ:NVCT | 31.71M | 18.2% | 40.3% | N/A | |
 TuHURA Biosciences, Inc. NASDAQ:HURA | 4.62M | 3.6% | -4.0% | -5.2% |
Anixa Biosciences, Inc. Fair Value Envelope
Related Guides
Continue your ANIX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.